Pub Date : 2025-09-26DOI: 10.1038/s41585-025-01088-6
Marine Potez,Gabriel Roman Souza,Philippe E Spiess,Shari Pilon-Thomas,Jad Chahoud
Adoptive cell therapy using tumour-infiltrating lymphocytes (TILs) has been a very successful model of enhancing immune-based therapies. Clinical benefits have been shown for patients with advanced melanoma, leading to the first FDA approval for this immune modality in 2024. Although clinical trials conducted decades ago for advanced renal-cell cancer did not show significant clinical benefits, recent advances in the TIL generation process, manipulation techniques, preparative regimens and combination with immune checkpoint inhibitors offer new hope for reexploring optimized TIL therapy for genitourinary cancers. The current landscape of TIL therapy has seen progress in TIL manufacturing, optimization and delivery methodologies that have the potential to improve the safety and efficacy of TIL therapy in the management of advanced genitourinary malignancies. Furthermore, innovative combination approaches and novel strategies could enhance the clinical viability of TIL therapy and warrant evaluation in clinical trials treating patients with genitourinary cancers.
{"title":"The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers.","authors":"Marine Potez,Gabriel Roman Souza,Philippe E Spiess,Shari Pilon-Thomas,Jad Chahoud","doi":"10.1038/s41585-025-01088-6","DOIUrl":"https://doi.org/10.1038/s41585-025-01088-6","url":null,"abstract":"Adoptive cell therapy using tumour-infiltrating lymphocytes (TILs) has been a very successful model of enhancing immune-based therapies. Clinical benefits have been shown for patients with advanced melanoma, leading to the first FDA approval for this immune modality in 2024. Although clinical trials conducted decades ago for advanced renal-cell cancer did not show significant clinical benefits, recent advances in the TIL generation process, manipulation techniques, preparative regimens and combination with immune checkpoint inhibitors offer new hope for reexploring optimized TIL therapy for genitourinary cancers. The current landscape of TIL therapy has seen progress in TIL manufacturing, optimization and delivery methodologies that have the potential to improve the safety and efficacy of TIL therapy in the management of advanced genitourinary malignancies. Furthermore, innovative combination approaches and novel strategies could enhance the clinical viability of TIL therapy and warrant evaluation in clinical trials treating patients with genitourinary cancers.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"4 1","pages":""},"PeriodicalIF":15.3,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145153483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-22DOI: 10.1038/s41585-025-01089-5
Logan G Briggs,Sarah P Psutka,Matthew J Van Ligten,Kelsey L Beck,Debarshi Sinha,Vikram S Gill,Khalid Y Alkhatib,Adri M Durant,Paul A Bain,Jaxon Quillen,Christopher Dodoo,Phillip M Pierorazio,Haidar Abdul-Muhsin,Mark D Tyson,Quoc-Dien Trinh,Sara C Parke
Prehabilitative and rehabilitative exercise, psychological support and nutrition interventions have proven beneficial in many cancer populations. Testicular cancer survivors have high rates of metabolic syndrome, cardiovascular disease, hypogonadism and psychosocial issues, and might yield greater benefit from such interventions than the average cancer survivor population. Results from the few studies available in this field suggest that exercise can improve fatigue, metabolic syndrome, cardiovascular risk profile and physical performance measures (such as VO2 max), whereas psychological support programmes have been shown to improve fatigue and mental health. However, a paucity of data exists on best practices for provision of nutrition, exercise and psychological support within the testicular cancer space, patients and caregivers, highlighting the urgent need for additional work in this field. Overall, prehabilitation and rehabilitation interventions for testicular cancer are safe and efficacious, and should be implemented by clinicians at diagnosis and throughout survivorship.
{"title":"Exercise, diet and psychological support for patients with testicular cancer.","authors":"Logan G Briggs,Sarah P Psutka,Matthew J Van Ligten,Kelsey L Beck,Debarshi Sinha,Vikram S Gill,Khalid Y Alkhatib,Adri M Durant,Paul A Bain,Jaxon Quillen,Christopher Dodoo,Phillip M Pierorazio,Haidar Abdul-Muhsin,Mark D Tyson,Quoc-Dien Trinh,Sara C Parke","doi":"10.1038/s41585-025-01089-5","DOIUrl":"https://doi.org/10.1038/s41585-025-01089-5","url":null,"abstract":"Prehabilitative and rehabilitative exercise, psychological support and nutrition interventions have proven beneficial in many cancer populations. Testicular cancer survivors have high rates of metabolic syndrome, cardiovascular disease, hypogonadism and psychosocial issues, and might yield greater benefit from such interventions than the average cancer survivor population. Results from the few studies available in this field suggest that exercise can improve fatigue, metabolic syndrome, cardiovascular risk profile and physical performance measures (such as VO2 max), whereas psychological support programmes have been shown to improve fatigue and mental health. However, a paucity of data exists on best practices for provision of nutrition, exercise and psychological support within the testicular cancer space, patients and caregivers, highlighting the urgent need for additional work in this field. Overall, prehabilitation and rehabilitation interventions for testicular cancer are safe and efficacious, and should be implemented by clinicians at diagnosis and throughout survivorship.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"2 1","pages":""},"PeriodicalIF":15.3,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145116625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-15DOI: 10.1038/s41585-025-01090-y
David Hennes, Abdullah Al-Khanaty, David C. Chen, Eoin Dinneen, Christa Babst, Nathan Lawrentschuk, Marlon L. Perera, Declan G. Murphy
Transrectal ultrasound-guided prostate biopsy is associated with limitations including high infection rates, sampling limitations and patient discomfort, which have led to the development of the transperineal approach. Randomized trials show that transperineal biopsy offers at least equivalent detection of clinically significant prostate cancer, providing robust evidence for a clinical practice change.
{"title":"End of the TRUS era: transperineal biopsy takes the lead in prostate cancer detection","authors":"David Hennes, Abdullah Al-Khanaty, David C. Chen, Eoin Dinneen, Christa Babst, Nathan Lawrentschuk, Marlon L. Perera, Declan G. Murphy","doi":"10.1038/s41585-025-01090-y","DOIUrl":"https://doi.org/10.1038/s41585-025-01090-y","url":null,"abstract":"Transrectal ultrasound-guided prostate biopsy is associated with limitations including high infection rates, sampling limitations and patient discomfort, which have led to the development of the transperineal approach. Randomized trials show that transperineal biopsy offers at least equivalent detection of clinically significant prostate cancer, providing robust evidence for a clinical practice change.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"36 1","pages":""},"PeriodicalIF":15.3,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145059332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Interstitial cystitis/bladder pain syndrome (IC/BPS), characterized by bladder discomfort and lower urinary tract symptoms, is often either overtreated or undertreated owing to the complexity and variability of symptoms and the lack of reliable diagnostic tools, leading to reduced quality of life and prolonged illness. The pathophysiology of IC/BPS remains unclear, with multiple hypotheses — such as autoimmune inflammation, oxidative stress and urothelial dysfunction — offering potential explanations. Consequently, a diverse range of urinary biomarkers has emerged, although their diagnostic reliability remains inconsistent. As technology advances, biomarkers are increasingly shifting towards multiplex assays, encompassing genomics, transcriptomics, proteomics and cell-based methods; however, cutting-edge research and clinical validation are not yet integrated into the limited diagnostic tools available. Clinical phenotypes from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network studies provide multi-level biomarker research — including molecular, imaging and other modalities — to support the diagnosis of IC/BPS. Integrating these observations will advance the development of precision medicine for the diagnosis of IC/BPS, thereby improving management of this complex condition.
{"title":"Exploring promising biomarkers based on pathogenic mechanisms in interstitial cystitis/bladder pain syndrome","authors":"Kerong Xin, Siyu Wu, Rong Li, Chiyu Tan, Yuanhong Jiang, Jiazheng Yu, Xu Liu, Shijie Li, Zhenhua Li, Xiaonan Chen","doi":"10.1038/s41585-025-01078-8","DOIUrl":"https://doi.org/10.1038/s41585-025-01078-8","url":null,"abstract":"<p>Interstitial cystitis/bladder pain syndrome (IC/BPS), characterized by bladder discomfort and lower urinary tract symptoms, is often either overtreated or undertreated owing to the complexity and variability of symptoms and the lack of reliable diagnostic tools, leading to reduced quality of life and prolonged illness. The pathophysiology of IC/BPS remains unclear, with multiple hypotheses — such as autoimmune inflammation, oxidative stress and urothelial dysfunction — offering potential explanations. Consequently, a diverse range of urinary biomarkers has emerged, although their diagnostic reliability remains inconsistent. As technology advances, biomarkers are increasingly shifting towards multiplex assays, encompassing genomics, transcriptomics, proteomics and cell-based methods; however, cutting-edge research and clinical validation are not yet integrated into the limited diagnostic tools available. Clinical phenotypes from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network studies provide multi-level biomarker research — including molecular, imaging and other modalities — to support the diagnosis of IC/BPS. Integrating these observations will advance the development of precision medicine for the diagnosis of IC/BPS, thereby improving management of this complex condition.</p>","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"118 1","pages":""},"PeriodicalIF":15.3,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-10DOI: 10.1038/s41585-025-01072-0
Lexiaochuan Wen, Hiroko Miyagi, Philippe E. Spiess, Alice Yu, Cathy L. Mendelsohn, Wei Shen Tan, Sarah P. Psutka, Seth P. Lerner, Liang Cheng, Lars Dyrskjøt, Joshua J. Meeks, Shahrokh F. Shariat, Paolo Gontero, Benjamin Pradere, Gary D. Steinberg, Ashish M. Kamat, Roger Li
Low-grade non-muscle invasive bladder cancer is a specific category of bladder cancer with a favourable prognosis; however, its management presents several challenges. The risk of stage progression is very low, but approximately half of patients will experience recurrence within the first 5 years after diagnosis. This high propensity for recurrence, coupled with the threat of progression, mandates ongoing surveillance. However, the optimal frequency and duration of follow-up monitoring remain undefined. Current management strategies for low-grade non-muscle invasive bladder cancer rely heavily on routine office cystoscopy, with few advances in diagnostic and treatment options over the past 25 years. Our basic understanding of disease biology has substantially advanced. However, at present, considerable variations in clinical practice exist, with implications for increased financial and treatment burden for patients and health care systems. Molecular signatures and biomarker discoveries are crucial to understand disease behaviour and inform novel treatment strategies. Emerging therapies, such as advanced drug-delivery systems, immunomodulatory agents and targeted therapies, offer the potential to improve patient outcomes, streamline management and reduce the need for surveillance cystoscopies. Actionable avenues for future research in the field include prospective validation of novel biomarkers and therapies with the ultimate aim of optimizing patient care and reducing health care costs. In this Review, the authors summarize the biological features of low-grade non-muscle-invasive bladder cancer, clinical risk stratification and evidence supporting treatment strategies. They also highlight contemporary developments in monitoring and therapeutic technologies.
{"title":"Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies","authors":"Lexiaochuan Wen, Hiroko Miyagi, Philippe E. Spiess, Alice Yu, Cathy L. Mendelsohn, Wei Shen Tan, Sarah P. Psutka, Seth P. Lerner, Liang Cheng, Lars Dyrskjøt, Joshua J. Meeks, Shahrokh F. Shariat, Paolo Gontero, Benjamin Pradere, Gary D. Steinberg, Ashish M. Kamat, Roger Li","doi":"10.1038/s41585-025-01072-0","DOIUrl":"10.1038/s41585-025-01072-0","url":null,"abstract":"Low-grade non-muscle invasive bladder cancer is a specific category of bladder cancer with a favourable prognosis; however, its management presents several challenges. The risk of stage progression is very low, but approximately half of patients will experience recurrence within the first 5 years after diagnosis. This high propensity for recurrence, coupled with the threat of progression, mandates ongoing surveillance. However, the optimal frequency and duration of follow-up monitoring remain undefined. Current management strategies for low-grade non-muscle invasive bladder cancer rely heavily on routine office cystoscopy, with few advances in diagnostic and treatment options over the past 25 years. Our basic understanding of disease biology has substantially advanced. However, at present, considerable variations in clinical practice exist, with implications for increased financial and treatment burden for patients and health care systems. Molecular signatures and biomarker discoveries are crucial to understand disease behaviour and inform novel treatment strategies. Emerging therapies, such as advanced drug-delivery systems, immunomodulatory agents and targeted therapies, offer the potential to improve patient outcomes, streamline management and reduce the need for surveillance cystoscopies. Actionable avenues for future research in the field include prospective validation of novel biomarkers and therapies with the ultimate aim of optimizing patient care and reducing health care costs. In this Review, the authors summarize the biological features of low-grade non-muscle-invasive bladder cancer, clinical risk stratification and evidence supporting treatment strategies. They also highlight contemporary developments in monitoring and therapeutic technologies.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"22 12","pages":"846-861"},"PeriodicalIF":14.6,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145025539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-08DOI: 10.1038/s41585-025-01087-7
Siyu Huang, David C. Chen, David Hennes, Declan G. Murphy, Nathan Lawrentschuk, Marlon L. Perera
New evidence shows that NeuroSAFE, an intraoperative frozen section technique during radical prostatectomy, improves erectile function recovery. Traditional NeuroSAFE using frozen section analysis might not work for all centres, but new technologies for intraoperative margin assessment might facilitate more pragmatic alternatives during radical prostatectomy.
{"title":"New evidence and novel techniques for assessing intraoperative margins during radical prostatectomy","authors":"Siyu Huang, David C. Chen, David Hennes, Declan G. Murphy, Nathan Lawrentschuk, Marlon L. Perera","doi":"10.1038/s41585-025-01087-7","DOIUrl":"https://doi.org/10.1038/s41585-025-01087-7","url":null,"abstract":"New evidence shows that NeuroSAFE, an intraoperative frozen section technique during radical prostatectomy, improves erectile function recovery. Traditional NeuroSAFE using frozen section analysis might not work for all centres, but new technologies for intraoperative margin assessment might facilitate more pragmatic alternatives during radical prostatectomy.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"31 1","pages":""},"PeriodicalIF":15.3,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145009287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-02DOI: 10.1038/s41585-025-01081-z
Arianna Biasatti, Nicolas A. Soputro, Francesco Porpiglia, Sisto Perdonà, Firas Abdollah, Ryan Nelson, Craig Rogers, Lee C. Zhao, Ahmed Ghazi, Ben Challacombe, Christopher Eden, Agostino Mattei, Christian D. Fankhauser, Alberto Breda, Bernardo Rocco, Francesco Montorsi, Alberto Briganti, Antony A. Pellegrino, Alexandre Mottrie, Ruben De Groote, Alexander Haese, Markus Graefen, Marcio C. Moschovas, Vipul Patel, Giuseppe Simone, Antonio Galfano, Silvia Secco, Riccardo Bertolo, Savio D. Pandolfo, Vito Pansadoro, Filipe L. F. Carvalho, Jean V. Joseph, Mohammad Ramadan, Jaschar Shakuri-Rad, Bertram Yuh, Jeffrey Nix, David I. Lee, Soroush Rais-Bahrami, Sij Hemal, Mohamed Eltemamy, Alp T. Beksac, Zeyad Schwen, Li-Ming Su, Maurizio Buscarini, Michael Palese, Ash Tewari, Peter Wiklund, Edward E. Cherullo, Srinivas Vourganti, Jennifer A. Linehan, Zhenjie Wu, Michael Stifelman, Mutahar Ahmed, Reza Mehrazin, Ketan Badani, Richard E. Link, Simone Crivellaro, Jihad Kaouk, Riccardo Autorino
The advent of the purpose-built da Vinci single-port robotic platform marks a pivotal advancement in minimally invasive urological surgery. Designed to overcome the ergonomic and technical limitations of prior single-site approaches, the single-port system enables complex procedures through a single incision, with enhanced dexterity, optimized use of confined spaces and improved cosmetic and peri-operative outcomes. The single-port system has been increasingly used across a wide range of urological indications, including robot-assisted radical prostatectomy, partial nephrectomy, nephroureterectomy and reconstructive surgeries such as pyeloplasty and ureteral re-implantation. Innovative access strategies, such as the single-port transvesical and low anterior access approaches, have facilitated regionalized and multi-quadrant surgeries without the need for repositioning or robot re-docking. These advances have translated into reduced morbidity, faster recovery and increased feasibility of opioid-sparing, same-day discharge protocols. As surgical expertise deepens and technology evolves, the single-port robotic platform stands as a refinement of minimally invasive surgery, and also as a potential paradigm shift in urological practice.
{"title":"The current landscape of single-port robotic surgery in urology","authors":"Arianna Biasatti, Nicolas A. Soputro, Francesco Porpiglia, Sisto Perdonà, Firas Abdollah, Ryan Nelson, Craig Rogers, Lee C. Zhao, Ahmed Ghazi, Ben Challacombe, Christopher Eden, Agostino Mattei, Christian D. Fankhauser, Alberto Breda, Bernardo Rocco, Francesco Montorsi, Alberto Briganti, Antony A. Pellegrino, Alexandre Mottrie, Ruben De Groote, Alexander Haese, Markus Graefen, Marcio C. Moschovas, Vipul Patel, Giuseppe Simone, Antonio Galfano, Silvia Secco, Riccardo Bertolo, Savio D. Pandolfo, Vito Pansadoro, Filipe L. F. Carvalho, Jean V. Joseph, Mohammad Ramadan, Jaschar Shakuri-Rad, Bertram Yuh, Jeffrey Nix, David I. Lee, Soroush Rais-Bahrami, Sij Hemal, Mohamed Eltemamy, Alp T. Beksac, Zeyad Schwen, Li-Ming Su, Maurizio Buscarini, Michael Palese, Ash Tewari, Peter Wiklund, Edward E. Cherullo, Srinivas Vourganti, Jennifer A. Linehan, Zhenjie Wu, Michael Stifelman, Mutahar Ahmed, Reza Mehrazin, Ketan Badani, Richard E. Link, Simone Crivellaro, Jihad Kaouk, Riccardo Autorino","doi":"10.1038/s41585-025-01081-z","DOIUrl":"https://doi.org/10.1038/s41585-025-01081-z","url":null,"abstract":"<p>The advent of the purpose-built da Vinci single-port robotic platform marks a pivotal advancement in minimally invasive urological surgery. Designed to overcome the ergonomic and technical limitations of prior single-site approaches, the single-port system enables complex procedures through a single incision, with enhanced dexterity, optimized use of confined spaces and improved cosmetic and peri-operative outcomes. The single-port system has been increasingly used across a wide range of urological indications, including robot-assisted radical prostatectomy, partial nephrectomy, nephroureterectomy and reconstructive surgeries such as pyeloplasty and ureteral re-implantation. Innovative access strategies, such as the single-port transvesical and low anterior access approaches, have facilitated regionalized and multi-quadrant surgeries without the need for repositioning or robot re-docking. These advances have translated into reduced morbidity, faster recovery and increased feasibility of opioid-sparing, same-day discharge protocols. As surgical expertise deepens and technology evolves, the single-port robotic platform stands as a refinement of minimally invasive surgery, and also as a potential paradigm shift in urological practice.</p>","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"58 1","pages":""},"PeriodicalIF":15.3,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144930669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-27DOI: 10.1038/s41585-025-01079-7
Evan Suzman, Ang Li, Gal Wald, Jim C. Hu
Urinary incontinence is a common sequela of robot-assisted radical prostatectomy and adversely affects quality of life. Advances in surgical technique preserve the pelvic anatomy to mitigate postoperative urinary incontinence. Pelvic-fascia-sparing techniques such as Retzius-sparing and hood with single-port or multi-port robotic approaches can improve outcomes.
{"title":"Pelvic-fascia-sparing techniques and outcomes with RARP","authors":"Evan Suzman, Ang Li, Gal Wald, Jim C. Hu","doi":"10.1038/s41585-025-01079-7","DOIUrl":"https://doi.org/10.1038/s41585-025-01079-7","url":null,"abstract":"Urinary incontinence is a common sequela of robot-assisted radical prostatectomy and adversely affects quality of life. Advances in surgical technique preserve the pelvic anatomy to mitigate postoperative urinary incontinence. Pelvic-fascia-sparing techniques such as Retzius-sparing and hood with single-port or multi-port robotic approaches can improve outcomes.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"24 1","pages":""},"PeriodicalIF":15.3,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144905844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：